Document is current
Any future updates will be listed below
-
Authors
Simpson, Eric L. https://orcid.org/0000-0003-0853-0252
Silverberg, Jonathan I. https://orcid.org/0000-0003-3686-7805
Geng, Bob https://orcid.org/0000-0002-4618-4445
Carrascosa, José-Manuel https://orcid.org/0000-0003-4266-0771
Bieber, Thomas https://orcid.org/0000-0002-8800-3817
Brunner, Patrick M. https://orcid.org/0000-0002-3488-3345
Staumont-Sallé, Delphine https://orcid.org/0000-0002-4780-4212
Ji, Chao https://orcid.org/0000-0002-1913-9702
Biswas, Pinaki https://orcid.org/0009-0009-3494-4142
Feeney, Claire https://orcid.org/0000-0003-4605-6571
Hernández-Martín, Irene https://orcid.org/0000-0001-9620-0485
Rebollo Laserna, Francisco José https://orcid.org/0000-0003-3651-3687
Koppensteiner, Herwig https://orcid.org/0009-0004-4228-7553
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03720470 at ClinicalTrials.govnct04345367 at ClinicalTrials.govDocuments that mention this clinical trial
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
https://doi.org/10.1007/s13555-025-01516-w
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
https://doi.org/10.1007/s40257-022-00738-4
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
https://doi.org/10.1007/s13555-022-00694-1
Documents that mention this clinical trial
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
https://doi.org/10.1007/s13555-025-01516-w
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 26 April 2025
Accepted: 4 August 2025
First Online: 23 September 2025
Declarations
:
: Eric L. Simpson received grants from Pfizer, Eli Lilly, Kyowa Kirin, LEO Pharma, Merck, and Regeneron and personal fees from Pfizer, Bausch Health (Valeant), Dermira, Eli Lilly, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. Jonathan I. Silverberg served as an investigator for Celgene, Eli Lilly, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi Genzyme; as a consultant for Pfizer, AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi Genzyme; and as a speaker for Regeneron and Sanofi Genzyme. Bob Geng has worked as a consultant for Pfizer and Genentech; as a speaker/consultant for Regeneron, Sanofi Genzyme, CSL Behring, and Horizon Therapeutics; and is on advisory boards for Novartis and Shire. José-Manuel Carrascosa has participated as an invited speaker, primary or secondary investigator in clinical trials, and advisor for Sanofi, LEO Pharma, Novartis, Almirall, Eli Lilly, Janssen, AbbVie, Celgene, Amgen, Mylan, Biogen, Pfizer, and Sandoz, Boehringer Ingelheim, and Bristol Myers Squibb. Thomas Bieber is/was a lecturer and/or consultant for Pfizer, AbbVie, Affibody, Almirall, Amagma Therapeutics, AnaptysBio, AOBiome, Anergis, Apogee, Arena, Aristea, Artax, Asana Biosciences, ASLAN Pharma, Astria, Attovia, BambusTx, Bayer Health, BioVersys, Boehringer Ingelheim, Bristol Myers Squibb, Byome Labs, Connect Pharma, Daiichi Sankyo, Dermavant, DICE Therapeutics, Domain Therapeutics, EQRx, Galderma, Galapagos, Gilead, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Eli Lilly, MSD, Medac, Micreos, Nektar Therapeutics, Novartis, Numab, OM-Pharma, Overtone, Pierre Fabre, Q32bio, RAPT, Samsung Bioepis, Sanofi/Regeneron, TIRmed, UCB, Union Therapeutics, Upstream Bio, and Yuhan. Patrick M. Brunner has received personal fees from Pfizer, AbbVie, Almirall, Amgen, Arena Pharma, Biotest, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, and UCB and is an investigator for Pfizer (grant paid to his institution). Delphine Staumont-Sallé has served as a consultant, scientific adviser, and/or clinical study investigator for Pfizer, AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Sanofi Genzyme, and UCB. Chao Ji has no conflicts to disclose. Pinaki Biswas, Irene Hernández-Martín, and Herwig Koppensteiner are employees and shareholders of Pfizer Inc. Claire Feeney and Francisco José Rebollo Laserna were employees of Pfizer Inc. at the time this study was conducted.
: The JADE DARE and JADE COMPARE trials were conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines. All local regulatory requirements were followed. The JADE DARE and DARE COMPARE trials were approved by the institutional review board or ethics committee at each of the investigational centers participating in the studies. All patients provided written informed consent.
